After its potential kidney disease drug went down in flames late last year, Novo Nordisk is pinning the blame on alleged fraudulent claims by the drug’s original maker. | After its potential kidney ...
The FDA and its Center for Devices and Radiological Health (CDRH) were among several health-focused agencies caught in sweeping layoffs over the weekend as the Trump administration seeks | It’s ...
J&J said it found no immediate procedure-related causes from the atrial fibrillation therapy but that risks can escalate if a ...
The National Institutes of Health has lost two distinguished leaders as mass layoffs directed by the Trump administration hit federal health agencies.
Septerna stood out from the crowd of biotech IPOs last year due to the lack of clinical data to hand. Now, the data are ...
The deal, which features up to $385 million in milestones, gives Biogen exclusive rights to commercialize Stoke’s ...
Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg.
Solid Biosciences has surged back into the Duchenne muscular dystrophy (DMD) gene therapy race. | Solid Biosciences has ...
“As administrations change, federal agencies’ leadership often changes to align with the incoming president’s priorities,” ...
Boston biotech Kojin Therapeutics is closing its doors, citing four funding challenges and a few valuable lessons learned. ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback